Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study

被引：0
|
作者：
Patrice Lazure
Anthony Sireci
Vivek Subbiah
Suzanne Murray
Christian Grohé
Steven I. Sherman
Elizabeth Kelly
Patrick Bubach
Sophie Péloquin
机构：
[1] AXDEV Group Inc.,
[2] Eli Lilly,undefined
[3] The University of Texas MD Anderson Cancer Center,undefined
[4] Berlin Evangelical Lung Clinic,undefined
来源：
BMC Medical Education | / 23卷
关键词：
Lung cancers; Thyroid cancers; Medullary thyroid cancer (MTC); Pathology; Needs assessment; Diagnostic techniques and procedures; RET-alteration; Genetic biomarker testing; Quality assurance; Continuing professional development;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study
    Lazure, Patrice
    Sireci, Anthony
    Subbiah, Vivek
    Murray, Suzanne
    Grohe, Christian
    Sherman, Steven I.
    Kelly, Elizabeth
    Bubach, Patrick
    Peloquin, Sophie
    BMC MEDICAL EDUCATION, 2023, 23 (01)
  • [2] Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study
    Suzanne Murray
    Vivek Subbiah
    Steven I. Sherman
    Sophie Péloquin
    Anthony Sireci
    Christian Grohé
    Patrick Bubach
    Patrice Lazure
    Thyroid Research, 16
  • [3] Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study
    Murray, Suzanne
    Subbiah, Vivek
    Sherman, Steven I.
    Peloquin, Sophie
    Sireci, Anthony
    Grohe, Christian
    Bubach, Patrick
    Lazure, Patrice
    THYROID RESEARCH, 2023, 16 (01)
  • [4] EFFICACY AND SAFETY OF RET KINASE INHIBITORS IN RET-ALTERED THYROID AND LUNG CANCER: SYSTEMATIC REVIEW OF CLINICAL TRIALS
    Aiman, Wajeeha
    Ali, Muhammad Ashar
    Anwar, Muhammad Yasir
    Al Omour, Bader
    Chemarthi, Venkata Sireesha
    Guron, Gunwant
    Shaaban, Hamid
    Maroules, Michael
    CHEST, 2023, 164 (04) : 4172A - 4172A
  • [5] Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer
    Kassir, Nastya
    Mcdougall, David
    Kuruvilla, Denison
    Kim, Sean
    Kumar, Shaun
    Rahman, Ahmadur
    Ruf, Thorsten
    Cheeti, Sravanthi
    Ankrom, Wendy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (06): : 685 - 696
  • [6] Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer
    Curigliano, G.
    Subbiah, V.
    Gainor, J. F.
    Lee, D. H.
    Taylor, M. H.
    Zhu, V.
    Doebele, R. C.
    Lopes, G.
    Baik, C.
    Garralda, E.
    Gadgeel, S. M.
    Kim, D-W.
    Turner, C. D.
    Palmer, M.
    Miller, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 790 - 790
  • [7] LIBRETTO-321, a phase II study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)
    Zheng, X.
    Ji, Q.
    Sun, Y.
    Ge, M.
    Zhang, B.
    Cheng, Y.
    Lei, S.
    Shi, F.
    Zhang, W.
    Gao, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S14 - S14
  • [8] Unpleasant symptoms of immunotherapy for people with lung cancer: A mixed-method study
    Zhang, Jingyu
    Wang, Sichao
    Zhou, Zihao
    Lei, Cheng
    Yu, Hongfan
    Zeng, Cheng
    Xia, Xin
    Qiao, Guibing
    Shi, Qiuling
    INTERNATIONAL JOURNAL OF NURSING STUDIES, 2023, 139
  • [9] Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer
    Zarinshenas, Reza
    Amini, Arya
    Mambetsariev, Isa
    Abuali, Tariq
    Fricke, Jeremy
    Ladbury, Colton
    Salgia, Ravi
    CANCERS, 2023, 15 (05)
  • [10] Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)
    Lee, D. H.
    Subbiah, V.
    Gainor, J. F.
    Taylor, M. H.
    Zhu, V. W.
    Doebele, R. C.
    Lopes, G.
    Baik, C.
    Garralda, E.
    Gadgeel, S. M.
    Kim, D-W.
    Turner, C. D.
    Palmer, M.
    Miller, S.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2019, 30
12345